Press Releases

Reset all filters

Collaboration with Mary Tyler Moore Vision Initiative

Two women cuddling

Developing treatments for people with mental health conditions

laboratory equipment

Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare

Boehringer_Healthcare_HCP_CallwithSale

Boehringer Ingelheim collaborates with Circle Pharma

Boehringer Ingelheim collaborates with Circle Pharma

Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide

Boehringer_Workplace_Lab_Discussion-01_RGB_002.

Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities

Boehringer and NCD Alliance

Boehringer Ingelheim expands cancer research at its Vienna site

Vienna oncology research centre.

Nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study

Mehrkanalpipette

Zongertinib shows encouraging efficacy and tolerability profile in lung cancer patients

Boehringer lab

Geographic Atrophy treatment to move to Phase II

Happy Family

Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio

walking_dog

Boehringer Ingelheim announces appointments Board of Managing Directors

Deshpande Wiesler

Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC

Boehringer_Workplace_Lab_Research-01

Boehringer Ingelheim acquires Nerio Therapeutics

in the lab

CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®

CHMP-positive-opinion-SPEVIGO

First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones

Boehringer_Workplace_Lab_Research

Boehringer Ingelheim produces its own green energy

Ingelheim biomass plant inauguration cropped

Boehringer Ingelheim advances SIRPα immuno-oncology program

Pipettes with violet fluid

Phase 1 start for novel triple agonist obesity treatment

Woman working in the lab on a laptop

Survodutide shows breakthrough improvement in liver fibrosis

3-Lab-techs

Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals

Boehringer Ingelheim Economist Impact

Partnership for first-in-class cancer and CRM treatments

Man working in the lab

BULTAVO 3™ is a new vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3)

Sheep with bell are looking at camera

Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia

Woman in the lab

World Veterinary Day 2024 celebrates the essential work of veterinarians, yet new data show only 49% of veterinary professionals believe their profession is appreciated

Veterinarian treats dog, chicken is being held in barn

Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline

boehringer_biopharmaceutical production_Biberach

Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets

Shanghai

Results announced from EMPACT-MI phase III trial

EMPA

SPEVIGO® approved for expanded indications in China and the US

Boehringer Workplace Lab Research

New partnership to develop schizophrenia treatments

Two persons talking

Survodutide Phase II trial shows groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis

MASH

The Sleip app uses artificial intelligence (AI) to provide objective analysis of a horse’s movement with just a smartphone.

Girl with horse in front of a camera

Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients

doctor pointing on spine

Global Top Employer 2024 certification reflects Boehringer Ingelheim’s impactful people development

Employee in learning environment

Boehringer expands production site in Greece for new medicine

Koropi groundbreaking

SENVELGO® wins Best New Product for Companion Animals award

Man with cat

Kicking off 2024 with five new R&D partnerships

Discussion of doctors and caregivers

New study paves the way for liver cirrhosis treatments

Scientists/doctors looking on a tablet

Boehringer Ingelheim licenses a new compound as part of its commitment to people living with fibro-inflammatory diseases from Kyowa Kirin

Kyowa

Boehringer Ingelheim and 3T Biosciences enter into a second partnership to develop next-generation cancer immunotherapies

Partnership 3T Bio

Partnership for new liver disease treatments with Ribo

Scientists in the lab

Boehringer Ingelheim announces appointments Board of Managing Directors

Huebler_Schmelmer

Partnership with IBM to accelerate new antibody therapies

Doctors in a discussion

Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid medication for diabetic cats

Diabetic cat with owner

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss

Boehringer Ingelheim achieves major milestone in chronic kidney disease

Asi+empa image.jpg

Life forward - Boehringer Ingelheim unveils its evolved company brand

Life forward release 1

SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award

Prix Galien 2023.jpeg

Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease

Phase III trials_image.png

Phase 1 start of treatment for Geographic Atrophy patients

Eye in detail

Partnership with Precision Health Research, Singapore

Woman and Man in Computer room

Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss

Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss

Boehringer Ingelheim receives SBTi validation for CO2 reduction targets

KMP_tree_ClimateSeed_Ⓒ Permian Global 1440 x 810 plus Copyright 460kb.jpg

New partnership working on solutions to combat African animal trypanosomiasis

Man with cattle herd

Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity

Obesity release.png

Boehringer Ingelheim receives FDA approval for SENVELGO®: the first oral liquid medication for diabetes in cats

Man with cat on sofa

First half of 2023: strong growth and expansion in key therapy areas

HY 2023 press release image

FRONTLINE® wins Brand of the Year Award for the third time in a row

Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease

Kidney Diseases

Boehringer Ingelheim receives FDA approval for NexGard® PLUS: a beef-flavored soft chew that protects dogs from internal and external parasites

Female veterinarian with dog in practise, woman and kid standing in background

Spesolimab prevents GPP flares

A person touching a scientific data visualization

Phase II trial data shows nearly 19% weight loss in people with overweight or obesity

Scientist with tablet stock image

Jardiance® recommended for the treatment of adults with chronic kidney disease in the EU

Phase II trial results in people living with obesity or overweight

Phase II trial results in people living with obesity or overweight

IL-11 inhibitor antibody clinical development launched

colorful picture

Breakthrough Designation granted in US and China

Finger pointing at a digital tick box

Boehringer and German Chancellor Olaf Scholz lay the foundation stone for EUR 285 million innovation center

Dreyer_vonBaumbach_Scholz

Boehringer inaugurates largest European development centre for biotechnology

Boehringer Ingelheim reaches more patients than ever, innovation drives growth

ARPC press release

LastMile initiative reaches over 40,000 smallholder farmers in Sub-Saharan Africa increasing access to veterinary medicine

People standing in a circle in rural Africa

Spesolimab meets key endpoint for GPP flare prevention

A female doctor speaks to a male patient about results of medical checks whilst sat in a general practice

FDA accepts application for new CKD treatment

Empa_Kidney

Global Top Employer 2023

Top Employer 2023

New cancer therapeutics collaboration with 3T Bio

monecules

Boehringer Ingelheim announces appointments to Board of Managing Directors

New digital Tx collab with Click

woman with mobilephone

EC grants conditional marketing authorization for spesolimab

EC grants marketing authorization for spesolimab

Phase III trial demonstrated Jardiance is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes

New positive data in Phase III type 2 diabetes trial

Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease

EMPA-KIDNEY trial meets primary endpoint

FIBRONEER™ Phase III program initiated in over 40 countries

On the left side of the image is the label which reads #Press’. Under the label is the text which reads First Patient enrolled in FIBRONEER-IPF Phase III trial. The right side of the image shows a tree shaped as lungs

AI and Data Science Fellowship with University of Tuebingen

AI&Data Science Fellowship Tuebingen

CHMP recommends conditional approval for first GPP treatment

Female scientific laboratory staff member wearing a lab coat uses a microscope by staring into it

Bridging science and veterinary practice for swine health: The winners of the European PRRS Award 2022

Collage of four individual headshots, three men, one woman

Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements

Cowtribe in action

Boehringer Ingelheim launches Fencovis®, a new vaccine to prevent calf diarrhea

Birth of a calf

New data for nintedanib in children with fibrosing interstitial lung disease

New Phase III data in children living with ILD

First approval for SPEVIGO® to treat GPP flares

Businessman using digital x-ray human body scan interface 3D rendering

First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

People working in a lab

Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance

Small group of female laboratory assistants checking blood, using microscope and doing tests

Option to Acquire Trutino Biosciences

T-cell 1440_810.png

Boehringer Ingelheim and CarthroniX announce partnership to pursue small molecule therapeutics in canine oncology

Vet examining dog

Jardiance® (empagliflozin) decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence study

Medical worker showing a heart

A*STAR antibodies bolster ADC and T-Cell engager development

A*Star

Investigational treatment slowed lung function decline in IPF

Visual representation of human lungs

TwistPak®: Mixing platform for swine vaccines brings convenience and flexibility

Man injects piglet with vaccines that have been mixed in TwistPak

Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal

AI machine deep learning.jpg

Boehringer Ingelheim launches RenuTend™: a new stem cell therapy to improve the healing of tendon and suspensory ligament injuries in horses

A woman rides a horse

Good business performance gives Boehringer Ingelheim tailwind for investment in Research and Development

048_© 2020, Peter Ginter - final adjustments at the “pipe crossover”

Boehringer Ingelheim selects Veeva Development Cloud worldwide to bring innovative therapies to patients faster

data

New spesolimab data show significant improvement in GPP flares

Urban girl standing out from the crowd at a city street.

Boehringer Ingelheim and the World Association for Buiatrics support outstanding research on ruminant animal health and well-being

Cows in stable

Jardiance® (empagliflozin) Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease

EMPA-KIDNEY

Jardiance® (empagliflozin) becomes the first and only approved treatment in Europe for adults with symptomatic chronic heart failure regardless of ejection fraction

EMA_PressRelease

Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial

Patient and Doctor talking to each other. You can only see their hands

Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data

Data digital

US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction

Hands holding a heart

FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis

White lung shown on mint background

New criteria for the susceptibility testing of Ubrolexin® when treating mastitis in dairy cows

Cattle herd

Media Contacts

Harro Ten Wolde

Head of Global Media Relations

E-Mail:
harro.ten_wolde@boehringer-ingelheim.com

Phone Number:
+49 (6132) 77-181352

Tereza Urbankova

Senior Media Relations Manager

E-Mail:
tereza.urbankova@boehringer-ingelheim.com

Phone Number:
+49 (6132) 77-184817

Mark Valentiner

Senior Media Relations Manager

E-Mail:
mark_william.valentiner@boehringer-ingelheim.com

Tel.: +49 (6132) 77-170136

Valerie-Chiara Nestle

Media Relations Manager

E-Mail:
valerie-chiara.nestle@boehringer-ingelheim.com

Phone Number:
+49 (7351) 54-175075

Anthonia Aboyeji

Head of Human Pharma Communications

E-Mail:
anthonia.aboyeji@boehringer-ingelheim.com

Phone Number:
+49 (6132) 77-172370

Heidi De Wit-Sommerfeld

Head of Animal Health Communications

E-Mail:
Heidi.DeWit-Sommerfeld@boehringer-ingelheim.com

Phone Number:
+49 (6132) 77-171799

Camilla Krogh Lauritzen

Head of Innovation Unit Communications

E-Mail: camilla.krogh_lauritzen@boehringer-ingelheim.com

Phone Number: +45 2272 4806